Literature DB >> 16759097

The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).

Juozas Domarkas1, Fabienne Dudouit, Christopher Williams, Qiu Qiyu, Ranjita Banerjee, Fouad Brahimi, Bertrand Jacques Jean-Claude.   

Abstract

According to the "combi-targeting" concept, the EGFR tyrosine kinase (TK) inhibitory potency of compounds termed "combi-molecules" is critical for selective growth inhibition of tumor cells with disordered expression of EGFR or its closest family member erbB2. Here we report on the optimization of the EGFR TK inhibitory potency of the combi-molecules of the nitrosourea class by comparison with their aminoquinazoline and ureidoquinazoline precursors. This led to the discovery of a new structural parameter that influences their EGFR TK inhibitory potency, i.e., the torsion angle between the plane of the quinazoline ring and the ureido or the nitrosoureido moiety of the synthesized drugs. Compounds (3'-Cl and Br series) with small angles (0.5-3 degrees ) were generally stronger EGFR TK inhibitors than those with large angles (18-21 degrees ). This was further corroborated by ligand-receptor van der Waals interaction calculations that showed significant binding hindrance imposed by large torsion angles in the narrow ATP cleft of EGFR. Selective antiproliferative studies in a pair of mouse fibroblast NIH3T3 cells, one of which NIH3T3/neu being transfected with the erbB2 oncogene, showed that IC(50) values for inhibition of EGFR TK could be good predictors of their selective potency against the serum-stimulated growth of the erbB2-tranfected cell line (Pearson r = 0.8). On the basis of stability (t(1/2)), EGFR TK inhibitory potency (IC(50)), and selective erbB2 targeting, compound 23, a stable nitrosourea, was considered to have the structural requirements for further development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16759097     DOI: 10.1021/jm0600390

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Antitumor agents. 266. Design, synthesis, and biological evaluation of novel 2-(furan-2-yl)naphthalen-1-ol derivatives as potent and selective antibreast cancer agents.

Authors:  Yizhou Dong; Qian Shi; Yi-Nan Liu; Xiang Wang; Kenneth F Bastow; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2009-06-11       Impact factor: 7.446

2.  Synthesis, Biological Evaluation, and Autophagy Mechanism of 12N-Substituted Sophoridinamines as Novel Anticancer Agents.

Authors:  Chongwen Bi; Na Zhang; Peng Yang; Cheng Ye; Yanxiang Wang; Tianyun Fan; Rongguang Shao; Hongbin Deng; Danqing Song
Journal:  ACS Med Chem Lett       Date:  2017-01-05       Impact factor: 4.345

3.  Synthesis and Antitumor Activity Evaluation of a Novel Combi-nitrosourea Prodrug: BGCNU.

Authors:  Yameng Wang; Ting Ren; Xinxin Lai; Guohui Sun; Lijiao Zhao; Na Zhang; Rugang Zhong
Journal:  ACS Med Chem Lett       Date:  2017-01-13       Impact factor: 4.345

4.  Characterization of the potency of epidermal growth factor (EGFR)-DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain.

Authors:  Meaghan MacPhee; Zakaria Rachid; Margarita Todorova; Qiyu Qiu; Gina Belinsky; Bertrand J Jean-Claude
Journal:  Invest New Drugs       Date:  2010-04-29       Impact factor: 3.850

5.  Insights into the EGFR SAR of N-phenylquinazolin-4-amine-derivatives using quantum mechanical pairwise-interaction energies.

Authors:  Saw Simeon; Nathjanan Jongkon; Warot Chotpatiwetchkul; M Paul Gleeson
Journal:  J Comput Aided Mol Des       Date:  2019-09-07       Impact factor: 3.686

6.  Purification and mechanism of human aldehyde oxidase expressed in Escherichia coli.

Authors:  Joshua F Alfaro; Carolyn A Joswig-Jones; Wenyun Ouyang; Joseph Nichols; Gregory J Crouch; Jeffrey P Jones
Journal:  Drug Metab Dispos       Date:  2009-09-09       Impact factor: 3.922

7.  Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent.

Authors:  Wei Liu; Jin-Feng Ning; Qing-Wei Meng; Jing Hu; Yan-Bin Zhao; Chao Liu; Li Cai
Journal:  Drug Des Devel Ther       Date:  2015-07-23       Impact factor: 4.162

8.  Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.

Authors:  Dong-Dong Li; Ya-Juan Qin; Jian Sun; Jing-Ran Li; Fei Fang; Qian-Ru Du; Yong Qian; Hai-Bin Gong; Hai-Liang Zhu
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.